GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Inventories, Other

NurExone Biologic (TSXV:NRX) Inventories, Other : C$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. NurExone Biologic's other inventories for the quarter that ended in Dec. 2024 was C$0.00 Mil.


NurExone Biologic Inventories, Other Historical Data

The historical data trend for NurExone Biologic's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Inventories, Other Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Inventories, Other
- - - -

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NurExone Biologic Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines